Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK138D1 with or without Ivonescimab in advanced breast cancer
ChiCTR2600129968Phase 2Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of AK138D1 in breast cancer and triple-negative breast cancer (TNBC) (11 arms), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Progression-free survival (PFS). Started Aug 2026; status: recruiting.
02
Drugs
AK138D1
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2600129968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129968.